We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
-13.03%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$696M
AUM Growth
-$298M
Cap. Flow
-$81.5M
Cap. Flow %
-11.71%
Top 10 Hldgs %
54.99%
Holding
76
New
17
Increased
7
Reduced
14
Closed
29

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$30.3M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$21.6M
3
AIMT
Aimmune Therapeutics
AIMT
+$18.5M
4
NGNE icon
Neurogene
NGNE
+$17.6M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$17.1M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$20.2M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$18.8M
3
DVAX
Dynavax Technologies
DVAX
+$17.9M
4
JUNO
Juno Therapeutics, Inc.
JUNO
+$14.9M
5
NVAX icon
Novavax
NVAX
+$14.2M

Sector Composition

Rank Sector Weight
1 Healthcare 85.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
51
Alkermes
ALKS
$8.11B
– –
-19,200
Closed -$1.24M
AMGN icon
52
Amgen
AMGN
$209B
– –
-5,900
Closed -$906K
AUPH icon
53
Aurinia Pharmaceuticals
AUPH
$1.95B
– –
-1,142,676
Closed -$3.45M
BIIB icon
54
Biogen
BIIB
$30.9B
– –
-2,600
Closed -$1.05M
DVAX
55
DELISTED
Dynavax Technologies
DVAX
– –
-766,000
Closed -$17.9M
INCY icon
56
Incyte
INCY
$25.8B
– –
-10,700
Closed -$1.11M
NBIX icon
57
Neurocrine Biosciences
NBIX
$18.2B
– –
-24,400
Closed -$1.17M
OMER icon
58
Omeros
OMER
$845M
– –
-749,000
Closed -$13.5M
PBYI icon
59
Puma Biotechnology
PBYI
$398M
– –
-3,100
Closed -$362K
PTCT icon
60
PTC Therapeutics
PTCT
$6.18B
– –
-25,800
Closed -$1.24M
REGN icon
61
Regeneron Pharmaceuticals
REGN
$72.9B
– –
-2,450
Closed -$1.25M
SGMO
62
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-6,000,000
Closed -$66.5M
VXRT
63
DELISTED
Vaxart
VXRT
– –
-73,441
Closed -$1.67M
LUMO
64
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-3,333
Closed -$1.33M
TRVN
65
DELISTED
Trevena, Inc.
TRVN
– –
-845
Closed -$3.31M
TTOO
66
DELISTED
T2 Biosystems, Inc
TTOO
– –
-28
Closed -$2.24M
CNCE
67
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-668,406
Closed -$9.95M
CLVS
68
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-13,200
Closed -$1.16M
MDCO
69
DELISTED
Medicines Co
MDCO
– –
-705,925
Closed -$20.2M
ARRY
70
DELISTED
Array Biopharma Inc
ARRY
– –
-126,095
Closed -$909K
TSRO
71
DELISTED
TESARO, Inc.
TSRO
– –
-23,500
Closed -$1.38M
KERX
72
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-59,200
Closed -$591K
JUNO
73
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-280,000
Closed -$14.9M
SCMP
74
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
– –
-450,000
Closed -$7.39M
MACK
75
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-14,794
Closed -$1.44M
1 2
3
4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, RA Capital Management held 76 positions worth $696M, down 30% from $994M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RA Capital Management withdrew a net $81.5M in Q3 2015, closing 29 positions and reducing 14 holdings. Its most notable exit was Medicines Co, an estimated $20.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 76% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Zogenix, Inc. worth $22.7M.

  • RA Capital Management's largest Q3 2015 buy was Zogenix, Inc.: 1,679,500 shares worth $22.7M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q3 2015, an estimated $14.6M increase.
  • RA Capital Management's biggest Q3 2015 reduction was BioCryst Pharmaceuticals, cutting an estimated $18.8M.
  • RA Capital Management fully exited Medicines Co in Q3 2015, selling an estimated $20.2M.
  • RA Capital Management's ten largest holdings make up 55% of its $696M portfolio in Q3 2015.
  • RA Capital Management opened 17 new positions and closed 29 in Q3 2015.
  • RA Capital Management's portfolio value fell 30% quarter-over-quarter to $696M.

Based on RA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.